Pub Date : 2021-07-01DOI: 10.4103/glioma.glioma_11_21
J. Robledo-Arias, Veronica Arango-Machado, Michael Ortega-Sierra, Ivan Lozada-Martinez
{"title":"Need for specialized neuro-oncology units in low- and middle-income countries: Lessons learned from the COVID-19 pandemic","authors":"J. Robledo-Arias, Veronica Arango-Machado, Michael Ortega-Sierra, Ivan Lozada-Martinez","doi":"10.4103/glioma.glioma_11_21","DOIUrl":"https://doi.org/10.4103/glioma.glioma_11_21","url":null,"abstract":"","PeriodicalId":12731,"journal":{"name":"Glioma","volume":"4 1","pages":"62 - 63"},"PeriodicalIF":0.0,"publicationDate":"2021-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41610653","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-07-01DOI: 10.4103/glioma.glioma_14_21
Chao Ma, Guihuai Wang
Spinal cord and spine system diseases are complex and diverse, and prognosis is often poor. Therefore, early diagnosis is essential, especially for spinal system tumors, which are malignant nervous system tumors that have the highest mortality and disability rates. Accurate diagnosis avoids unnecessary operations. Traditional medical imaging diagnosis remains at the level of anatomical morphology, and there is a considerable amount of useful information that can be extracted and utilized. Radiomics is a new method of medical imaging diagnosis that is committed to improving image analysis and is capable of extracting a large number (more than 200 types) of quantitative features from medical images. Numerous studies on the application of radiomics in various systems of the body have been conducted. We reviewed current research on radiomics in spinal cord and spine system diseases and discussed the progress and challenges to provide a basis for improving the diagnosis and identification of spinal cord and spine system diseases and offer evidence-based support for precision medicine.
{"title":"Application and prospect of radiomics in spinal cord and spine system diseases: A narrative review","authors":"Chao Ma, Guihuai Wang","doi":"10.4103/glioma.glioma_14_21","DOIUrl":"https://doi.org/10.4103/glioma.glioma_14_21","url":null,"abstract":"Spinal cord and spine system diseases are complex and diverse, and prognosis is often poor. Therefore, early diagnosis is essential, especially for spinal system tumors, which are malignant nervous system tumors that have the highest mortality and disability rates. Accurate diagnosis avoids unnecessary operations. Traditional medical imaging diagnosis remains at the level of anatomical morphology, and there is a considerable amount of useful information that can be extracted and utilized. Radiomics is a new method of medical imaging diagnosis that is committed to improving image analysis and is capable of extracting a large number (more than 200 types) of quantitative features from medical images. Numerous studies on the application of radiomics in various systems of the body have been conducted. We reviewed current research on radiomics in spinal cord and spine system diseases and discussed the progress and challenges to provide a basis for improving the diagnosis and identification of spinal cord and spine system diseases and offer evidence-based support for precision medicine.","PeriodicalId":12731,"journal":{"name":"Glioma","volume":"4 1","pages":"37 - 41"},"PeriodicalIF":0.0,"publicationDate":"2021-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46597707","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Spinal glioblastoma multiforme (GBM) that originates from the conus medullaris is rare as only 28 cases have been reported. It is highly aggressive and usually initially presents with low back pain, sensory and motor impairment of the lower extremities, and bladder dysfunction. We herein report a unique case of GBM in the conus medullaris with leptomeningeal dissemination that initially presented with increased intracranial pressure without hydrocephalus. The patient was first diagnosed with tuberculous meningitis and received antituberculosis therapy, but the symptoms did not resolve and even worsened. Subsequent radiological imaging clearly disclosed an intramedullary lesion at the T12 level with the progression of leptomeningeal enhancement. Subtotal resection of the intramedullary lesion was performed, and pathological examination revealed the presence of GBM. To our knowledge, our case was the first with holocordal and intracranial leptomeningeal dissemination that initially presented with intracranial hypertension in the absence of hydrocephalus. Awareness of this unusually lethal condition is significant for proper diagnosis, timely treatment, and consideration of clinical prognosis.
{"title":"Glioblastoma multiforme of the conus medullaris with leptomeningeal dissemination that presented as intracranial hypertension: A case report and literature review","authors":"Yu Hu, Wumeng Yin, Jun-peng Ma, Jia-gang Liu, Si-qing Huang, Haifeng Chen","doi":"10.4103/glioma.glioma_15_21","DOIUrl":"https://doi.org/10.4103/glioma.glioma_15_21","url":null,"abstract":"Spinal glioblastoma multiforme (GBM) that originates from the conus medullaris is rare as only 28 cases have been reported. It is highly aggressive and usually initially presents with low back pain, sensory and motor impairment of the lower extremities, and bladder dysfunction. We herein report a unique case of GBM in the conus medullaris with leptomeningeal dissemination that initially presented with increased intracranial pressure without hydrocephalus. The patient was first diagnosed with tuberculous meningitis and received antituberculosis therapy, but the symptoms did not resolve and even worsened. Subsequent radiological imaging clearly disclosed an intramedullary lesion at the T12 level with the progression of leptomeningeal enhancement. Subtotal resection of the intramedullary lesion was performed, and pathological examination revealed the presence of GBM. To our knowledge, our case was the first with holocordal and intracranial leptomeningeal dissemination that initially presented with intracranial hypertension in the absence of hydrocephalus. Awareness of this unusually lethal condition is significant for proper diagnosis, timely treatment, and consideration of clinical prognosis.","PeriodicalId":12731,"journal":{"name":"Glioma","volume":"4 1","pages":"57 - 61"},"PeriodicalIF":0.0,"publicationDate":"2021-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43558093","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-07-01DOI: 10.4103/glioma.glioma_10_21
Beibei Yu, Yang Lu, L. Jing, Guihuai Wang
Although the 2021 World Health Organization classification update of the central nervous system tumors redefined "pilomyxoid astrocytoma" as high-grade astrocytoma with piloid features (HGAP), the craniocerebral HGAP exhibits poorer clinical outcomes when compared to pilocytic astrocytoma. However, in the spinal cord, the paucity of information of HGAP cases inhibits the judgment of prognosis and optimal management approaches for patients with spinal HGAP. Here, we summarized the clinical characteristics, management methods, and prognosis of ten cases of spinal HGAP reported in the literature and two cases of spinal HGAP who underwent tumor surgery in our institution. Here, the detailed clinical information we provided may help clinical decision-making for such rare childhood lesions. This study was approved by the Human Research Ethics Committees in our institution on June 29, 2021.
{"title":"Pediatric high-grade astrocytoma with piloid features of the spinal cord: A report of two cases and literature review","authors":"Beibei Yu, Yang Lu, L. Jing, Guihuai Wang","doi":"10.4103/glioma.glioma_10_21","DOIUrl":"https://doi.org/10.4103/glioma.glioma_10_21","url":null,"abstract":"Although the 2021 World Health Organization classification update of the central nervous system tumors redefined \"pilomyxoid astrocytoma\" as high-grade astrocytoma with piloid features (HGAP), the craniocerebral HGAP exhibits poorer clinical outcomes when compared to pilocytic astrocytoma. However, in the spinal cord, the paucity of information of HGAP cases inhibits the judgment of prognosis and optimal management approaches for patients with spinal HGAP. Here, we summarized the clinical characteristics, management methods, and prognosis of ten cases of spinal HGAP reported in the literature and two cases of spinal HGAP who underwent tumor surgery in our institution. Here, the detailed clinical information we provided may help clinical decision-making for such rare childhood lesions. This study was approved by the Human Research Ethics Committees in our institution on June 29, 2021.","PeriodicalId":12731,"journal":{"name":"Glioma","volume":"4 1","pages":"49 - 53"},"PeriodicalIF":0.0,"publicationDate":"2021-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46510645","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-07-01DOI: 10.4103/glioma.glioma_13_21
P. Aggarwal, D. Chatterjee, V. Gupta, Rekha Gupt
Epithelioid glioblastoma (eGB) is an uncommon morphological variant of isocitrate dehydrogenase wild-type GB that commonly presents as a cerebral mass in young adults and children. Here, we report the case of a 22-year-old man who presented with a cerebellar tumor. With the provisional diagnosis of pilocytic astrocytoma and adult medulloblastoma, he underwent suboccipital craniotomy with gross total excision of the tumor. On histopathological examination, he was diagnosed with eGB. Cerebellar presentation of eGB is a rare event that has not been previously described in the literature. The present case also highlights the need for differentiating eGB from its morphological mimics by carefully interpreting histopathological and immunohistochemical examination findings.
{"title":"Diagnostic challenges in epithelioid glioblastoma of the cerebellum: A case report","authors":"P. Aggarwal, D. Chatterjee, V. Gupta, Rekha Gupt","doi":"10.4103/glioma.glioma_13_21","DOIUrl":"https://doi.org/10.4103/glioma.glioma_13_21","url":null,"abstract":"Epithelioid glioblastoma (eGB) is an uncommon morphological variant of isocitrate dehydrogenase wild-type GB that commonly presents as a cerebral mass in young adults and children. Here, we report the case of a 22-year-old man who presented with a cerebellar tumor. With the provisional diagnosis of pilocytic astrocytoma and adult medulloblastoma, he underwent suboccipital craniotomy with gross total excision of the tumor. On histopathological examination, he was diagnosed with eGB. Cerebellar presentation of eGB is a rare event that has not been previously described in the literature. The present case also highlights the need for differentiating eGB from its morphological mimics by carefully interpreting histopathological and immunohistochemical examination findings.","PeriodicalId":12731,"journal":{"name":"Glioma","volume":"4 1","pages":"54 - 56"},"PeriodicalIF":0.0,"publicationDate":"2021-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47636137","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-07-01DOI: 10.4103/glioma.glioma_16_21
Dong-kang Liu, Guo-qing Yi, J. Wang, Guihuai Wang
Background and Aim: Intramedullary spinal cord glioma has no evident boundary with normal spinal cord tissue. The rate of successful surgical resection of intramedullary spinal cord glioma is low. Well-established animal models for intramedullary spinal cord glioma can help promote translation from related basic therapy research to clinical applications. In this study, we established a rat model of intramedullary spinal cord glioma. Materials and Methods: A total of 23 male Sprague-Dawley (SD) rats were randomized into blank control (n = 3) and experimental (n = 20) groups. The blank control group received intramedullary injection of Dulbecco's modified Eagle medium (DMEM) and the experimental group was injected with DMEM containing C6 glioma cells. The neurological states of these rats were evaluated using the Basso, Beattie, and Bresnahan scale (BBB). Tumor sizes were measured by magnetic resonance imaging. The histopathological analysis was performed to observe the growth of infiltrating tumors. All procedures involving animals were approved by the Ethics Committee of the Laboratory Animal Facility Biomedical Analysis Center, Tsinghua University (Beijing, China; approval No. 17-WGH1). Results: On postoperative 7 days, the experimental group presented with a significant progressive decrease in motor function (mean BBB score 15.00 ± 1.20) compared with the blank control group (20.67 ± 0.47, P < 0.01). All rats in the experimental group showed exponential tumor growth and had an average survival of up to 5 weeks after tumor cell implantation. The tumor sizes were 3.18 ± 0.21 mm3, 68.55 ± 3.38 mm3, and 345.28 ± 22.57 mm3 on postoperative 7, 14, and 28 days. The histopathological analysis illustrated that the growth of infiltrating tumors followed the longitudinal axis of the spinal cord. Conclusions: Thus, we have established a SD rat model of intramedullary spinal cord glioma, and we found that our findings are reproducible and homogeneous. These positive results provide solid bases for further studies of intramedullary spinal cord glioma.
{"title":"Establishment and evaluation of a Sprague-Dawley rat model of intramedullary spinal cord glioma","authors":"Dong-kang Liu, Guo-qing Yi, J. Wang, Guihuai Wang","doi":"10.4103/glioma.glioma_16_21","DOIUrl":"https://doi.org/10.4103/glioma.glioma_16_21","url":null,"abstract":"Background and Aim: Intramedullary spinal cord glioma has no evident boundary with normal spinal cord tissue. The rate of successful surgical resection of intramedullary spinal cord glioma is low. Well-established animal models for intramedullary spinal cord glioma can help promote translation from related basic therapy research to clinical applications. In this study, we established a rat model of intramedullary spinal cord glioma. Materials and Methods: A total of 23 male Sprague-Dawley (SD) rats were randomized into blank control (n = 3) and experimental (n = 20) groups. The blank control group received intramedullary injection of Dulbecco's modified Eagle medium (DMEM) and the experimental group was injected with DMEM containing C6 glioma cells. The neurological states of these rats were evaluated using the Basso, Beattie, and Bresnahan scale (BBB). Tumor sizes were measured by magnetic resonance imaging. The histopathological analysis was performed to observe the growth of infiltrating tumors. All procedures involving animals were approved by the Ethics Committee of the Laboratory Animal Facility Biomedical Analysis Center, Tsinghua University (Beijing, China; approval No. 17-WGH1). Results: On postoperative 7 days, the experimental group presented with a significant progressive decrease in motor function (mean BBB score 15.00 ± 1.20) compared with the blank control group (20.67 ± 0.47, P < 0.01). All rats in the experimental group showed exponential tumor growth and had an average survival of up to 5 weeks after tumor cell implantation. The tumor sizes were 3.18 ± 0.21 mm3, 68.55 ± 3.38 mm3, and 345.28 ± 22.57 mm3 on postoperative 7, 14, and 28 days. The histopathological analysis illustrated that the growth of infiltrating tumors followed the longitudinal axis of the spinal cord. Conclusions: Thus, we have established a SD rat model of intramedullary spinal cord glioma, and we found that our findings are reproducible and homogeneous. These positive results provide solid bases for further studies of intramedullary spinal cord glioma.","PeriodicalId":12731,"journal":{"name":"Glioma","volume":"4 1","pages":"42 - 48"},"PeriodicalIF":0.0,"publicationDate":"2021-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47514672","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-04-01DOI: 10.4103/glioma.glioma_4_20
A. Dalvi, A. Shetty, G. Gangakhedkar, Pallavi V. Waghalkar
Although it is well known that 49% cases of upper limb deep-vein thrombosis are due to malignancies and the likelihood of venous thromboembolism is increased in patients with high grade gliomas due to the heightened prothrombotic milieu, requisite preoperative laboratory coagulation studies are not performed routinely in these patients to decide whether appropriate antithrombotic medications are required preoperatively. In addition, it is controversial whether antithrombotic therapy should be initiated before neurosurgery in view of the risk of intraoperative bleeding. Here, we have described the case of a 29-year-old female with high grade frontal malignant astrocytoma who developed the extremely rare complication of upper limb compartment syndrome postoperatively. The patient had no history of thrombotic events, and her basic laboratory parameters were not deranged in the pre-operative period. This rare case, supported with a literature review, suggested that the risk of thrombosis is increased in high grade and large gliomas, making us rethink the overall battery of investigations and perioperative medical management of such cases. We strongly recommend peri-operative coagulation studies and appropriate antithrombotic measures along with vigilant perioperative monitoring to avoid thrombotic complication in this subset of patients.
{"title":"Unexpected upper limb compartment syndrome due to venous thrombosis in frontal glioma surgery: A case report","authors":"A. Dalvi, A. Shetty, G. Gangakhedkar, Pallavi V. Waghalkar","doi":"10.4103/glioma.glioma_4_20","DOIUrl":"https://doi.org/10.4103/glioma.glioma_4_20","url":null,"abstract":"Although it is well known that 49% cases of upper limb deep-vein thrombosis are due to malignancies and the likelihood of venous thromboembolism is increased in patients with high grade gliomas due to the heightened prothrombotic milieu, requisite preoperative laboratory coagulation studies are not performed routinely in these patients to decide whether appropriate antithrombotic medications are required preoperatively. In addition, it is controversial whether antithrombotic therapy should be initiated before neurosurgery in view of the risk of intraoperative bleeding. Here, we have described the case of a 29-year-old female with high grade frontal malignant astrocytoma who developed the extremely rare complication of upper limb compartment syndrome postoperatively. The patient had no history of thrombotic events, and her basic laboratory parameters were not deranged in the pre-operative period. This rare case, supported with a literature review, suggested that the risk of thrombosis is increased in high grade and large gliomas, making us rethink the overall battery of investigations and perioperative medical management of such cases. We strongly recommend peri-operative coagulation studies and appropriate antithrombotic measures along with vigilant perioperative monitoring to avoid thrombotic complication in this subset of patients.","PeriodicalId":12731,"journal":{"name":"Glioma","volume":"4 1","pages":"34 - 36"},"PeriodicalIF":0.0,"publicationDate":"2021-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47191729","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-04-01DOI: 10.4103/glioma.glioma_8_21
N. F. Farrukh Hameed, Yuyao Zhou, Lei Jin, Ying Xu, J Zhang, Hong Chen, James R. Xue, Jinsong Wu
Background and Aim: Blockade of CD95/CD95 ligand (CD95 L) signaling is a promising therapeutic approach for the treatment of glioblastoma (GBM), while methylation of a single cytosine-phosphate-guanine site (CpG2) upstream of the CD95 L promoter has been identified as a prognostic biomarker for GBM. Here, we conducted the first investigation of CD95 L expression and CpG2 methylation levels in the CD95 L promoter in GBM patients. Materials and Methods: In this observational study, tissue samples were collected from 69 patients with a primary diagnosis of World Health Organization Grade IV GBM treated at the Department of Glioma Surgery, Huashan Hospital, Shanghai Medical College, Fudan University and tested for CD95 L expression using immunohistochemistry (IHC). The CpG2 methylation status of the samples was also evaluated, and its impact on overall survival (OS) was assessed by univariate analysis. The study was approved by the Hospital Institutional Review Board (approval No. 220) on July 7, 2015. Results: The IHC results showed a CD95 L detection rate of at least 43.5% for tissue samples with IHC scores of 2+ or 3+ and 78.3% for those with IHC scores of 1+, 2+, or 3+. Patients with high CpG2 methylation levels (≥52% higher than the median value; n = 32) had significantly longer median survival compared with those with low CpG2 methylation levels (n = 29) (22.95 vs. 14.5 months; P = 0.0084). GBM patients who underwent gross total tumor resection (n = 57) showed similar results. Those in the high CpG2 methylation group had longer median OS compared with that of patients in the low CpG2 methylation group (23.5 vs. 18.0 months; P = 0.0141). Conclusions: Our results showed a significant prevalence of CD95 L expression in GBM patients, whereas CpG2 hypermethylation within the CD95 L promoter was positively associated with survival. These findings support that CD95/CD95 L signaling blockade has potential as a therapeutic strategy targeting treatment-resistant GBM.
{"title":"CpG2 hypermethylation in the CD95L promoter is associated with survival in patients with glioblastoma: An observational study","authors":"N. F. Farrukh Hameed, Yuyao Zhou, Lei Jin, Ying Xu, J Zhang, Hong Chen, James R. Xue, Jinsong Wu","doi":"10.4103/glioma.glioma_8_21","DOIUrl":"https://doi.org/10.4103/glioma.glioma_8_21","url":null,"abstract":"Background and Aim: Blockade of CD95/CD95 ligand (CD95 L) signaling is a promising therapeutic approach for the treatment of glioblastoma (GBM), while methylation of a single cytosine-phosphate-guanine site (CpG2) upstream of the CD95 L promoter has been identified as a prognostic biomarker for GBM. Here, we conducted the first investigation of CD95 L expression and CpG2 methylation levels in the CD95 L promoter in GBM patients. Materials and Methods: In this observational study, tissue samples were collected from 69 patients with a primary diagnosis of World Health Organization Grade IV GBM treated at the Department of Glioma Surgery, Huashan Hospital, Shanghai Medical College, Fudan University and tested for CD95 L expression using immunohistochemistry (IHC). The CpG2 methylation status of the samples was also evaluated, and its impact on overall survival (OS) was assessed by univariate analysis. The study was approved by the Hospital Institutional Review Board (approval No. 220) on July 7, 2015. Results: The IHC results showed a CD95 L detection rate of at least 43.5% for tissue samples with IHC scores of 2+ or 3+ and 78.3% for those with IHC scores of 1+, 2+, or 3+. Patients with high CpG2 methylation levels (≥52% higher than the median value; n = 32) had significantly longer median survival compared with those with low CpG2 methylation levels (n = 29) (22.95 vs. 14.5 months; P = 0.0084). GBM patients who underwent gross total tumor resection (n = 57) showed similar results. Those in the high CpG2 methylation group had longer median OS compared with that of patients in the low CpG2 methylation group (23.5 vs. 18.0 months; P = 0.0141). Conclusions: Our results showed a significant prevalence of CD95 L expression in GBM patients, whereas CpG2 hypermethylation within the CD95 L promoter was positively associated with survival. These findings support that CD95/CD95 L signaling blockade has potential as a therapeutic strategy targeting treatment-resistant GBM.","PeriodicalId":12731,"journal":{"name":"Glioma","volume":"4 1","pages":"22 - 26"},"PeriodicalIF":0.0,"publicationDate":"2021-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44832000","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-04-01DOI: 10.4103/glioma.glioma_5_21
Alejandro Urdiciain, P. Bermudez-Lekerika, B. Meléndez, Juan Rey, M. Idoate, Natalia A. Riobo-Del Galdo, J. Castresana
{"title":"Inhibition of histone deacetylase 6 by tubastatin A as an experimental therapeutic strategy against glioblastoma","authors":"Alejandro Urdiciain, P. Bermudez-Lekerika, B. Meléndez, Juan Rey, M. Idoate, Natalia A. Riobo-Del Galdo, J. Castresana","doi":"10.4103/glioma.glioma_5_21","DOIUrl":"https://doi.org/10.4103/glioma.glioma_5_21","url":null,"abstract":"","PeriodicalId":12731,"journal":{"name":"Glioma","volume":"4 1","pages":"27 - 33"},"PeriodicalIF":0.0,"publicationDate":"2021-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49263896","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-04-01DOI: 10.4103/glioma.glioma_9_21
M. Berger
{"title":"Progress on glioma surgery and multimodal treatments","authors":"M. Berger","doi":"10.4103/glioma.glioma_9_21","DOIUrl":"https://doi.org/10.4103/glioma.glioma_9_21","url":null,"abstract":"","PeriodicalId":12731,"journal":{"name":"Glioma","volume":"4 1","pages":"19 - 21"},"PeriodicalIF":0.0,"publicationDate":"2021-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48099461","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：